NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the firm to repurchase up to the lesser of $22.5 million worth or 900,000 shares of the company's outstanding common stock. The repurchase program is scheduled to expire Dec. 31, 2013, Luminex noted in a regulatory filing with the US Securities and Exchange Commission. As of Feb. 21, Luminex had nearly 41.7 million common shares outstanding, according to its Form 10-K filed on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.